ArticleBlood2023
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Open access · hybridAbstract read
In one paragraph
Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 47 citations in OpenAlex.
- Immune Checkpoints in Leukaemia as Gatekeepers of Immuno-Modulation.Immunology · 2026Review
- Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure.Blood reviews · 2026Review
- Immune Checkpoint Blockade in Hematological Malignancies: Current Status and Future Directions.Cancers · 2026Review
- Article
- Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia.Blood and lymphatic cancer : targets and therapy · 2026Review
- Hotspots evolution and frontiers of immunotherapy for the treatment of acute myeloid leukemia: A bibliometric analysis.Human vaccines & immunotherapeutics · 2025Article
- Molecular and Clinical Insights intoInternational journal of molecular sciences · 2025Review
- Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies.Journal of hematology & oncology · 2025Review
- Dendritic Cells of Leukemic Origin (DCCancers · 2025Article
- Targeting PD-1 for HCT relapse: an immunologic knife's edge.Blood advances · 2025Article
- Review
- One step further in targeting acute leukemia by combining antibody-based immunotherapies and small molecule inhibitors.Cancer cell international · 2025Review
- Immune Escape of Acute Myeloid Leukemia after Transplantation.Blood cancer discovery · 2025Review
- Targeting myeloid cells for hematological malignancies: the present and future.Biomarker research · 2025Review
- Increased Co-Expression of PD-L1 and CTLA-4 Predicts Poor Overall Survival in Patients with Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation.ImmunoTargets and therapy · 2025Article
- Biology of post-transplant relapse: actionable features.Hematology. American Society of Hematology. Education Program · 2024Review
- Article
- Tracking Rare Single Donor and Recipient Immune and Leukemia Cells after Allogeneic Hematopoietic Cell Transplantation Using Mitochondrial DNA Mutations.Blood cancer discovery · 2024Article
- Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia.Blood cancer discovery · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 10 institutions in 1 country.
Jacqueline S GarciaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-2118-6302
Yael FlamandDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.
Livius PenterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-9060-0207
Michael KengDivision of Hematology/Oncology, University of Virginia, Charlottesville, VA.
Benjamin K TomlinsonDepartment of Hematology/Oncology, Case Comprehensive Cancer Center, Cleveland, OH.
Lourdes M MendezDepartment of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA.
Paul KollerDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.ORCID 0000-0003-3830-5320
Nicole CullenCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
Yohei AriharaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Kathleen PfaffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
Jacquelyn O WolffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.
Andrew M BrunnerDepartment of Medical Oncology, Massachusetts General Hospital, Boston, MA.
Ilene GalinskyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Asad BasheyThe Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA.
Joseph H AntinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Corey CutlerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Vincent HoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Brian A JonasDivision of Cellular Therapy, BMT and Malignant Hematology, University of California, Davis, Sacramento, CA.ORCID 0000-0002-4921-5809
Marlise R LuskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-5781-4529
Martha WadleighDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Eric S WinerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-4515-8245
Alexandra SavellDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Rebecca LeonardDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Taylor RobertsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Matthew S DavidsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Howard StreicherCancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD.
Scott J RodigDepartment of Pathology, Brigham and Women's Hospital, Boston, MA.
Jerome RitzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-5526-4669
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-3348-5054
Daniel J DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-7865-2306
Donna NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Robert J SoifferDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Dana-Farber Cancer Institute · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USCity of Hope · USMassachusetts General Hospital · USNational Cancer Institute · USNorthside Hospital · USUniversity Hospitals Cleveland Medical Center · USUniversity of California, Davis · USUniversity of Virginia · US
Funding
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5MXPO1 inhibitors Selinexor and Eltanexor in Combination with Venetoclax and Decitabine (ASTX727) in AMLUM1CA186709 · NCI · DANA-FARBER CANCER INST · PI KEITH T FLAHERTY, DONALD W. KUFE · 2014 to 2026
$25.9MThe Johns Hopkins Translational Science Team for the ET-CTNUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci · 2014 to 2026
$21.9MCancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · PI FRANK S HODI, Catherine Ju-Ying Wu · 2017 to 2026
$18.4MSingle Cell and ImmunogenomicsP01CA229092 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME · 2019 to 2023
$13.8MCancer Immunologic Data Commons (CIDC) Supplement RequestU24CA224316 · NCI · DANA-FARBER CANCER INST · PI CERAMI, ETHAN, MICHOR, FRANZISKA · 2017 to 2022
$6.8MEnhancing Venetoclax Activity in Chemoresistant Acute Myeloid LeukemiaK08CA245209 · NCI · DANA-FARBER CANCER INST · PI GARCIA, JACQUELINE SUEN · 2020 to 2024
$1.3MNCI R50 Clinician Scientist AwardR50CA276013 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Brian A. Jonas · 2023 to 2026
$349kNCI NIH HHS K08 CA245209NCI NIH HHS P01 CA066996NCI NIH HHS P01 CA229092NCI NIH HHS R50 CA276013NCI NIH HHS U24 CA224316NCI NIH HHS U24 CA224331NCI NIH HHS UM1 CA186691NCI NIH HHS UM1 CA186709
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myeloid, AcuteMyelodysplastic SyndromesAzacitidineDecitabineHumansIpilimumabAzacitidineDecitabineIpilimumab
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.